refractory glioblastoma
Conditions
Interventions
control group:standard treatment
Sponsors
Shanghai Jing'an District Central Hospital (Jing'an Huashan Hospital Branch, Fudan University)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) postoperative histopathology and molecular confirmed MGMT promoter unmethylation in newly diagnosed GBM patients; 2) Aged 18-65 years old; 3) Karnofsky Performance Status (KPS) =60; 4) the expected survival time =3 months; 5) patients were without major organ dysfunction. Liver and kidney function was normal. Specific test index: White blood cells > 4.0×10^9/L; Platelet> 100×10^9/L; Hemoglobin > 10 g/dl; Serum bilirubin was lower than 1.5 times of the maximum normal value; ALT and AST was lower than 2 times of the maximum normal value; Serum creatinine = 1.5 mg/dl. 6) Patients fully understand clinical research protocol and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients had undergone chemotherapy with TMZ before adjuvant radiotherapy; 2) Patient during pregnancy or lactation; 3) Patients with suppurative and chronic infectious wounds delayed healing; 4) Patients with liver, kidney and heart dysfunction; 5) Patients suffering from a history of mental illness and uneasily controlled epilepsy; 6) Patients was considered not suitable by researchers in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival(PFS);Overall Survival(OS);Adverse Reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life; | — |
Countries
China
Contacts
Public ContactYang Wang
Shanghai Jing'an District Central Hospital (Jing'an Huashan Hospital Branch, Fudan University)
Outcome results
None listed